Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow responders
Brian L. Pearlman, Carole Ehleben, Sophia Saifee – 28 November 2007 – In hepatitis C virus (HCV) genotype 1 infection, the duration of interferon‐based therapy is a critical determinant in achieving sustained virologic response (SVR). Slow or late responders to peginterferon and ribavirin may benefit from an extended treatment course. We sought to determine if therapy extension could improve response rates in a United States population of slow responders.